A Phase 1 interventional study of MK-7602 and Efavirenz in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-22.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of the study is to learn what happens to levels of MK-7602 in a healthy person's body over time. Researchers will compare what happens to MK-7602 in the body when it is given with or without another medicine called efavirenz, and when it is given with or without a meal.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The key inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The key exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered MK-7602 and efavirenz.
Drug: MK-7602 · Drug: Efavirenz
Participants will be administered MK-7602 in the fasted state, then with a moderate-fat meal, then with a low-fat meal.
Drug: MK-7602
Participants will be administered MK-7602 in the fasted state, then with a low-fat meal, then with a moderate-fat meal.
Drug: MK-7602
Participants will be administered MK-7602 with a moderate-fat meal, then with a low-fat meal, then in the fasted state.
Drug: MK-7602
Participants will be administered MK-7602 with a moderate-fat meal, then in the fasted state, then with a low-fat meal.
Drug: MK-7602
Participants will be administered MK-7602 with a low-fat meal, then in the fasted state, then with a moderate-fat meal.
Drug: MK-7602
Participants will be administered MK-7602 with a low-fat meal, then with a moderate-fat meal, then in the fasted state.
Drug: MK-7602
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of MK-7602
Blood samples will be collected to determine the AUC0-inf of MK-7602.
Time frame: At designated time points (up to 4 weeks)
Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC0-24hrs) of MK-7602
Blood samples will be collected to determine the AUC0-24hr of MK-7602.
Time frame: At designated time points (up to 4 weeks)
Maximum Plasma Concentration (Cmax) of MK-7602
Blood samples will be collected to determine the Cmax of MK-7602.
Time frame: At designated time points (up to 4 weeks)
Time to Maximum Plasma Concentration (Tmax) of MK-7602
Blood samples will be collected to determine the Tmax of MK-7602.
Time frame: Predose and at designated time points (up to 4 weeks)
Plasma Concentration at 24 Hours (C24) of MK-7602
Blood samples will be collected to determine the C24 of MK-7602.
Time frame: At designated time points (up to 4 weeks)
Apparent Terminal Half-life (t1/2) of MK-7602
Blood samples will be collected to determine the t1/2 of MK-7602.
Time frame: At designated time points (up to 4 weeks)
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 10 weeks
Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.
Time frame: Up to approximately 10 weeks
Part 2: AUC0-Inf of MK-7602
Blood samples will be collected to determine the AUC0-inf of MK-7602.
Time frame: At designated time points (up to 4 weeks)
Part 2: AUC0-24hrs of MK-7602
Blood samples will be collected to determine the AUC0-24hr of MK-7602.
Time frame: At designated time points (up to 4 weeks)
Part 2: Cmax of MK-7602
Blood samples will be collected to determine the Cmax of MK-7602.
Time frame: At designated time points (up to 4 weeks)
Part 2: Tmax of MK-7602
Blood samples will be collected to determine the Tmax of MK-7602.
Time frame: Predose and at designated time points (up to 4 weeks)
Part 2: C24 of MK-7602
Blood samples will be collected to determine the C24 of MK-7602.
Time frame: At designated time points (up to 4 weeks)
Part 2: t1/2 of MK-7602
Blood samples will be collected to determine the t1/2 of MK-7602.
Time frame: At designated time points (up to 4 weeks)
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Feb 2025 to primary completion in Aug 2025, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-7602